169 related articles for article (PubMed ID: 32032660)
21. TRIAD1 Is a Novel Transcriptional Target of p53 and Regulates Nutlin-3a-Induced Cell Death.
Lee J; An S; Choi YM; Jung JH; Li L; Meng H; Dong Y; Ahn KJ; An IS; Bae S
J Cell Biochem; 2017 Jul; 118(7):1733-1740. PubMed ID: 27935098
[TBL] [Abstract][Full Text] [Related]
22. Nutlin-3 induces BCL2A1 expression by activating ELK1 through the mitochondrial p53-ROS-ERK1/2 pathway.
Lee SY; Choi HC; Choe YJ; Shin SJ; Lee SH; Kim HS
Int J Oncol; 2014 Aug; 45(2):675-82. PubMed ID: 24867259
[TBL] [Abstract][Full Text] [Related]
23. Nutlin-3-induced redistribution of chromatin-bound IFI16 in human hepatocellular carcinoma cells in vitro is associated with p53 activation.
Shi XL; Yang J; Mao N; Wu JH; Ren LF; Yang Y; Yin XL; Wei L; Li MY; Wang BN
Acta Pharmacol Sin; 2015 Feb; 36(2):252-8. PubMed ID: 25544361
[TBL] [Abstract][Full Text] [Related]
24. Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy.
Dey A; Wong ET; Bist P; Tergaonkar V; Lane DP
Cell Cycle; 2007 Sep; 6(17):2178-85. PubMed ID: 17786042
[TBL] [Abstract][Full Text] [Related]
25. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.
Secchiero P; Zerbinati C; di Iasio MG; Melloni E; Tiribelli M; Grill V; Zauli G
Curr Drug Metab; 2007 May; 8(4):395-403. PubMed ID: 17504227
[TBL] [Abstract][Full Text] [Related]
26. MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation.
Borthakur G; Duvvuri S; Ruvolo V; Tripathi DN; Piya S; Burks J; Jacamo R; Kojima K; Ruvolo P; Fueyo-Margareto J; Konopleva M; Andreeff M
PLoS One; 2015; 10(10):e0139254. PubMed ID: 26440941
[TBL] [Abstract][Full Text] [Related]
27. Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells.
Tseng HY; Jiang CC; Croft A; Tay KH; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
Mol Cancer Ther; 2010 Dec; 9(12):3363-74. PubMed ID: 21159614
[TBL] [Abstract][Full Text] [Related]
28. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells.
Elison JR; Cobrinik D; Claros N; Abramson DH; Lee TC
Arch Ophthalmol; 2006 Sep; 124(9):1269-75. PubMed ID: 16966622
[TBL] [Abstract][Full Text] [Related]
29. Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation.
Ma T; Yamada S; Ichwan SJ; Iseki S; Ohtani K; Otsu M; Ikeda MA
Biochem Biophys Res Commun; 2012 Jan; 417(3):931-7. PubMed ID: 22166212
[TBL] [Abstract][Full Text] [Related]
30. Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents.
Youlyouz-Marfak I; Gachard N; Le Clorennec C; Najjar I; Baran-Marszak F; Reminieras L; May E; Bornkamm GW; Fagard R; Feuillard J
Cell Death Differ; 2008 Feb; 15(2):376-85. PubMed ID: 17992189
[TBL] [Abstract][Full Text] [Related]
31. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2.
Cao C; Shinohara ET; Subhawong TK; Geng L; Kim KW; Albert JM; Hallahan DE; Lu B
Mol Cancer Ther; 2006 Feb; 5(2):411-7. PubMed ID: 16505116
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase-3/GSDME activation.
Zhang CC; Li CG; Wang YF; Xu LH; He XH; Zeng QZ; Zeng CY; Mai FY; Hu B; Ouyang DY
Apoptosis; 2019 Apr; 24(3-4):312-325. PubMed ID: 30710195
[TBL] [Abstract][Full Text] [Related]
33. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.
Ray RM; Bhattacharya S; Johnson LR
Apoptosis; 2011 Jan; 16(1):35-44. PubMed ID: 20812030
[TBL] [Abstract][Full Text] [Related]
34. Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest.
Giono LE; Manfredi JJ
Mol Cell Biol; 2007 Jun; 27(11):4166-78. PubMed ID: 17371838
[TBL] [Abstract][Full Text] [Related]
35. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.
Zhang L; Zhang J; Hu C; Cao J; Zhou X; Hu Y; He Q; Yang B
Anticancer Drugs; 2009 Jul; 20(6):416-24. PubMed ID: 19579266
[TBL] [Abstract][Full Text] [Related]
36. Effect of low doses of actinomycin D on neuroblastoma cell lines.
Cortes CL; Veiga SR; Almacellas E; Hernández-Losa J; Ferreres JC; Kozma SC; Ambrosio S; Thomas G; Tauler A
Mol Cancer; 2016 Jan; 15():1. PubMed ID: 26728659
[TBL] [Abstract][Full Text] [Related]
37. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
38. Low-dose mithramycin exerts its anticancer effect via the p53 signaling pathway and synergizes with nutlin-3 in gynecologic cancers.
Ohgami T; Kato K; Kobayashi H; Sonoda K; Inoue T; Yamaguchi S; Yoneda T; Wake N
Cancer Sci; 2010 Jun; 101(6):1387-95. PubMed ID: 20331637
[TBL] [Abstract][Full Text] [Related]
39. ERK1/2 activation mediated by the nutlin‑3‑induced mitochondrial translocation of p53.
Lee SY; Shin SJ; Kim HS
Int J Oncol; 2013 Mar; 42(3):1027-35. PubMed ID: 23314357
[TBL] [Abstract][Full Text] [Related]
40. MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53.
Manfé V; Biskup E; Johansen P; Kamstrup MR; Krejsgaard TF; Morling N; Wulf HC; Gniadecki R
J Invest Dermatol; 2012 May; 132(5):1487-96. PubMed ID: 22377766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
